National cancer institute selects immunitybio's n-803 il-15 receptor agonist to combine with keytruda in 700-site lung-map clinical trial of a chemo-free therapy

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced the lung cancer master protocol (lung-map) public-private partnership—which includes the national cancer institute (nci), the national clinical trials network (nctn) cooperative groups (swog, ecog-acrin, alliance, and nrg), friends of cancer research, and the foundation for the national institutes of health (fnih)—will study the company's il-15 receptor superagonist co
IBRX Ratings Summary
IBRX Quant Ranking